Johnson & Johnson Inc. announced Wednesday that it will purchase 82 percent of Dutch vaccine-maker Crucell for $34.45 per share, according to this J&J statement. The two companies had confirmed that they were in talks to complete the $2.4 billion takeover on September 17.
The shares being purchased are the only ones J&J does not yet own. The New Brunswick, N.J.-based pharmaceutical giant purchased its original stake of roughly 18 percent of Crucell in September 2009 for $444 million. Crucell researches, produces, and markets vaccines and antibodies aimed at infectious diseases, and is a major supplier to UNICEF.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
